ASXFDA Completes Review of Third PMA Module
other announcement
IMR
Imricor Medical Systems
Health Care Equipment & Services
Development of MRI-compatible medical devices to carry out MRI-guided cardiac catheter ablation procedures.
Short position
short percentage0.66%
reported shorts2.4M
shares on issue358.651M
Imricor Medical Systems (ASX:IMR) has 0.66% of its shares on issue reported as short positions as of 5 Oct 2026, or about 2,373,293 shares. Over the past 30 days that figure has risen 0.50 percentage points, and over 90 days it has risen 0.59 percentage points. IMR is classified in the Health Care Equipment & Services industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4Imricor Medical Systems (IMR) News
Latest articles and price-sensitive announcements with AI sentiment classification.
Application for quotation of securities - IMR
other announcement
FDA Accepts Imricor PMA Manufacturing Module
other announcement
Imricor and Philips Launch Commercial iMR Lab Solution
other announcement
Q2 CY2026 Quarterly Activities Report & Form 10-Q Submission
other announcement
Motley FoolImricor Medical Systems shares: Philips declares compatibility for iMR products
Big news is catching the eye of investors on Friday. The post Imricor Medical Systems shares: Philips declares compatibility for iMR products appeared first on The Motley Fool Australia.
Small Caps
Google NewsImricor Medical Systems (ASX: IMR): Medical Technology Stock Retreats as Healthcare Weakens - Kalkine
Imricor Medical Systems (ASX: IMR): Medical Technology Stock Retreats as Healthcare Weakens Kalkine
KalkineImricor (ASX:IMR) Moves Closer to Full US FDA Platform
Highlights Imricor (ASX:IMR) has advanced its US regulatory program with additional FDA submissions supporting its MRI-guided cardiac platform. The company's NorthStar platform continues supporting early commercial engagement with hospitals in the United States. Investor focus is expected to gradually shift from regulatory milestones toward commercial adoption and hospital rollout. Imricor (ASX:IMR) has taken another important step in its United States expansion strategy after advancing its reg...
Imricor Submits All Remaining 510(k) Devices to FDA
other announcement
Top Reason Imricor Medical Systems (ASX:IMR) Is Back in Focus After Key FDA Win
Highlights Imricor Medical Systems has secured expanded United States regulatory clearance for its MRI-guided cardiac ablation technology. The approval allows the company's NorthStar system and Vision-MR diagnostic catheter to be marketed for use in both children and adults. The latest milestone broadens the company's commercial opportunity as it continues expanding its presence in MRI-guided cardiac procedures. Australia's healthcare sector continues to a...
Imricor Medical Systems (ASX: IMR) Rises as MRI-Guided Ablation Firm Gains - Kalkine
Imricor Medical Systems (ASX: IMR) Rises as MRI-Guided Ablation Firm Gains Kalkine
Imricor (ASX:IMR) Gains FDA Paediatric Clearance as Healthcare Sector Builds Momentum
Highlights Imricor (ASX:IMR) secured FDA clearance allowing paediatric use of its MRI-guided cardiac devices. The approval expands the company's addressable market within specialised cardiac procedures. Several ASX healthcare companies remained active as the sector continued attracting market attention. Imricor (ASX:IMR) attracted strong market attention after receiving expanded approval from the US Food and Drug Administration (FDA) for paediatric use of its M...
StockheadHealth Check: It’s child’s play as Imricor shares surge on follow-up FDA clearance
Having gained FDA clearance for adult use of its novel catheters and guidance system, Imricor now can tackle the US ... Read More The post Health Check: It’s child’s play as Imricor shares surge on follow-up FDA clearance appeared first on Stockhead.
Imricor Receives FDA Pediatric Clearances for iMR Device
other announcement
Submission of the Third PMA Module to the US FDA for Review
other announcement
Granting of ASX Waiver - US Financial Reporting Requirements
other announcement
Update - Notification regarding unquoted securities - IMR
other announcement
Imricor Completes Successful A$60 Million Capital Raise
other announcement
Imricor Q1 CY26 Quarterly Activities Report and Appendix 4C
other announcement
Imricor Submits NorthStar for U.S. Pediatric Expansion
other announcement
Notice of Annual Stockholders Meeting and CDI Voting Form
other announcement